Rise of the biosimilars
2018 was a significant year for biosimilars. October’s patent expiry of adalimumab, the world’s top selling prescription medicine, saw a raft of biosimilars launch,...
PPRS evolution and what does it mean for pharma?
How has the Pharmaceutical Price Regulation Scheme (PPRS) evolved since its inception in the 1950s, and what does its latest iteration mean for pharma? Price...
Politics and the NHS Long Term Plan
Claudia Rubin looks at the immediate political response to the NHS 10 Year Plan which launched in January. Politics always moves at an incredible pace as...
What is the future of cancer?
4 February is World Cancer Day.
It’s a commonly discussed disease with well-publicised media campaigns around causes and symptoms, but it still affects more...
How to engage payers in the NHS
How well pharma companies engage with payers within a morphing NHS landscape will determine whether brands succeed or fail. 2019 promises to be a year...
Is pharma prepared for future NHS commissioning?
What’s the future for NHS commissioning and is pharma prepared? The NHS has had commissioning since 1991 but it has definitely failed to thrive and,...
The importance of patient engagement
The trend for true patient engagement can only be good news for pharma and for patient outcomes. It is notoriously difficult to predict how patient...
Sharing experience of expanding access to medicines
2018 was a challenging year for pharma companies. While our industry continues to discover and develop treatments that improve lives throughout the world, trust...
Closing the NHS leadership gender gap
From patient to pharma, everyone involved in the health service stands to benefit from closing the NHS leadership gender gap – and there...
Tackling gender diversity in pharma leadership
When it comes to gender diversity in pharma leadership, research has found that the pharmaceutical industry is lagging far behind. What’s being done to...
Latest articles
Novo Nordisk presents oral semaglitude data at ENDO
Oral semaglutide 7 mg and 14 mg doses showed superior reductions in blood sugar and weight compared to sitagliptin at 26 weeks in data...
Pf Award Winners on the positive patient outcomes that come from working together
The winners of the Joint Working Pf Award 2018, Senior Coloplast Care Nurse Ruth Christer and NHS Partnership Manager, Coloplast, Jonathan Walker, on the...
Detecting and managing atrial fibrillation
The ‘Podiatry and Atrial Fibrillation – Save a life, stop a stroke’ webinar was created to improve the detection and management of atrial fibrillation,...
Popular articles
Detecting and managing atrial fibrillation
The ‘Podiatry and Atrial Fibrillation – Save a life, stop a stroke’ webinar was created to improve the detection and management of atrial fibrillation,...
Samsung Bioepis announces three-year follow-up data for biosimilar ONTRUZANT® (trastuzumab)
Samsung Bioepis announces three-year follow-up data for biosimilar ONTRUZANT® (trastuzumab) in early or locally advanced HER2-positive breast cancer. Samsung Bioepis has announced the findings of...
The future of genomics and precision medicine
How is the use of genomics data enhancing our medical understanding and what does this mean for the future of precision medicine? Genomics is one of...
Novo Nordisk presents oral semaglitude data at ENDO
Oral semaglutide 7 mg and 14 mg doses showed superior reductions in blood sugar and weight compared to sitagliptin at 26 weeks in data...
Addressing the skills shortage in life sciences
How can collaboration help to fill the skills shortage gap to ensure that the UK can compete in the global future of life sciences? The...